Stock MGTX MEIRAGTX HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company MeiraGTx Holdings plc

Equities

MGTX

KYG596651029

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
4.71 USD -3.09% Intraday chart for MeiraGTx Holdings plc -5.99% -32.91%
Apr. 16 MeiraGTx Holdings plc Appoints Dr. Debra Yu to Serve on Each of the Compensation Committee and Science and Technology Committee of the Board CI
Mar. 14 MeiraGTx Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Number of employees: 422

Sales per Business

USD in Million2022Weight2023Weight Delta
Retinal Drugs and Gene Therapies
100.0 %
16 100.0 % 14 100.0 % -11.95%

Sales per region

USD in Million2022Weight2023Weight Delta
United Kingdom
100.0 %
16 100.0 % 14 100.0 % -11.95%

Managers

Managers TitleAgeSince
Richard Giroux FOU
 Founder 61 15-03-19
Alexandria Forbes CEO
 Chief Executive Officer 59 15-03-19
Robert Zeldin CTO
 Chief Tech/Sci/R&D Officer 61 20-08-04
Elizabeth Anderson IRC
 Investor Relations Contact - 18-12-31
Tim Randall AUD
 Comptroller/Controller/Auditor - 19-03-31
Robert Wollin LAW
 General Counsel 48 19-07-31
Stuart Naylor PRN
 Corporate Officer/Principal 61 15-03-31

Members of the board

Members of the board TitleAgeSince
Debra Yu BRD
 Director/Board Member 59 22-04-24
Thomas Shenk BRD
 Director/Board Member 77 15-05-31
Keith Harris CHM
 Chairman 71 15-05-31
Nicole Seligman BRD
 Director/Board Member 66 19-05-09
Alexandria Forbes CEO
 Chief Executive Officer 59 15-03-19
Stuart Naylor PRN
 Corporate Officer/Principal 61 15-03-31
Martin Indyk BRD
 Director/Board Member 72 19-02-20
Ellen Hukkelhoven BRD
 Director/Board Member 37 17-09-30
Neil Mendoza BRD
 Director/Board Member 64 15-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 63,601,015 41,131,656 ( 64.67 %) 0 64.67 %

Shareholders

NameEquities%Valuation
Perceptive Advisors LLC
17.82 %
11,331,103 17.82 % 69 M $
Johnson & Johnson Innovation - JJDC, Inc.
10.44 %
6,641,064 10.44 % 40 M $
Adage Capital Partners GP LLC
8.321 %
5,291,618 8.321 % 32 M $
SANOFI
7.387 %
4,697,737 7.387 % 29 M $
Prosight Management LP
6.369 %
4,050,714 6.369 % 25 M $
683 Capital Management LLC
3.931 %
2,500,000 3.931 % 15 M $
BlackRock Advisors LLC
3.301 %
2,099,031 3.301 % 13 M $
Alexandria Forbes
2.204 %
1,401,489 2.204 % 9 M $
Richard Giroux
1.463 %
930,578 1.463 % 6 M $
Royce & Associates LP
1.057 %
672,115 1.057 % 4 M $

Company contact information

MeiraGTx Holdings Plc

450 East 29th Street 14th floor

10016, New York

+646 860 7985

http://www.meiragtx.com
address MeiraGTx Holdings plc(MGTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for MeiraGTx Holdings plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.71 USD
Average target price
21.6 USD
Spread / Average Target
+358.60%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MEIRAGTX HOLDINGS PLC Stock MeiraGTx Holdings plc
-32.91% 303M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
+0.49% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-9.05% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MGTX Stock
  4. Company MeiraGTx Holdings plc